News EU approval for new asthma drug Exdensur lifts GSK EU approval takes GSK a step closer to fulfilling its blockbuster sales hopes for new long-acting respiratory drug Exdensur.
News 11 high-impact drugs to look out for in 2026 Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year.
News UK, US approve GSK's twice-yearly asthma drug GSK scores a first approval in the UK for new severe asthma and CRSwNP therapy Exdensur, but a second in the US covers the asthma indication only.
News GSK closes on approval of asthma hope depemokimab GSK is poised for the first major approval of depemokimab, a long-acting drug for severe asthma that can be dosed just twice a year.
Oncology ASCO 2026: Chinese firms take a front seat in oncology, with... Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
